Gen-Probe Stock Hits New 52-Week High (GPRO)

NEW YORK ( TheStreet) -- Gen-Probe (Nasdaq: GPRO) hit a new 52-week high Monday as it is currently trading at $82.45, above its previous 52-week high of $82.43 with 292,227 shares traded as of 12:19 p.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Gen-Probe has a market cap of $3.78 billion and is part of the services sector and diversified services industry. Shares are up 39.4% year to date as of the close of trading on Friday.

Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. The company has a P/E ratio of 78.5, below the average diversified services industry P/E ratio of 80 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Gen-Probe as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Gen-Probe Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target